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Serotonergic systemFerulic acid (4-hydroxy-3-methoxycinnamic acid) is a phenolic compound present in several plants with
claimed beneﬁcial effects in prevention and treatment of disorders linked to oxidative stress and inﬂamma-
tion. In this study, we aimed to verify the possible antidepressant-like effect of acute oral administration of
ferulic acid in the forced swimming test (FST) and tail suspension test (TST) in mice. Additionally, the mech-
anisms involved in the antidepressant-like action and the effects of the association of ferulic acid with the an-
tidepressants ﬂuoxetine, paroxetine, and sertraline in the TST were investigated. Ferulic acid produced an
antidepressant-like effect in the FST and TST (0.01–10 mg/kg, p.o.), without accompanying changes in ambu-
lation. The pretreatment of mice with WAY100635 (0.1 mg/kg, s.c., a selective 5-HT1A receptor antagonist) or
ketanserin (5 mg/kg, i.p., a 5-HT2A receptor antagonist) was able to reverse the anti-immobility effect of feru-
lic acid (0.01 mg/kg, p.o.) in the TST. The combination of ﬂuoxetine (5 mg/kg, p.o.), paroxetine (0.1 mg/kg,
p.o.) or sertraline (1 mg/kg, p.o.) with a sub-effective dose of ferulic acid (0.001 mg/kg, p.o.) produced a syn-
ergistic antidepressant-like effect in the TST, without causing hyperlocomotion in the open-ﬁeld test. Taken
together, these results demonstrate that ferulic acid exerts antidepressant-like effect in the FST and TST in
mice through modulation of the serotonergic system.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Depression is a disorder that has high incidence in the world pop-
ulation (Berton and Nestler, 2006) with impact in the life quality of
patients (Nemeroff, 2007). The treatment of depression with conven-
tional antidepressants provides a complete remission just for 50% of
the individuals (Rush et al., 2003), produces side effects (Brunello et
al., 2002) that may reduce the adhesion of patients to the treatment
(MacGillivray et al., 2003), and the majority of patients takes more
than 5–8 weeks to respond to the treatment. Thus, novel or additional
treatments with low side effects and costs are of particular interest
(Laakmann et al., 1998).
Ferulic acid (4-hydroxy-3-methoxycinnamic acid) is a phenolic
compound present in several plants and in natural extracts of herbs,
spices, and coffee (Graf, 1992; Virgili et al., 2000). Ferulic acid has
been approved as an antioxidant additive and food preservative in
Japan (Graf, 1992; JFCRF, 1996) and sodium ferulate, a salt of ferulic
acid, has been used in traditional medicine and is approved by Stateica, CCB, Universidade Federal
nópolis, 88040-900, SC, Brazil.
evier OA license.Drugs Administration of China for the treatment of cardiovascular
and cerebrovascular diseases (Wang and Ou-Yang, 2005).
Ferulic acid has been shown to exert a potent antioxidant activity
(Anselmi et al., 2004; Bourne and Rice-Evans, 1998; Graf, 1992; Itagaki
et al., 2009; Ogiwara et al., 2002; Srinivasan et al., 2007). The connec-
tion between inﬂammation and oxidative stress has suggested that
ferulic acid may also be an effective agent against inﬂammatory
diseases as previously reported (Chawla et al., 1987; Fernandez et al.,
1998; Murakami et al., 2002). Ferulic acid has been shown to be bene-
ﬁcial in prevention and/or treatment of disorders linked to oxidative
stress and inﬂammation (Jin et al., 2005; Kim et al., 2004; Perluigi et
al., 2006; Yan et al., 2001; Zhang et al., 2003). In addition, Yu et al.
(2006) reported that ferulic acid produced a potent protection against
excitotoxic effects of monosodium glutamate, since maternal adminis-
tration of ferulic acid reduced glutamate-induced toxicity in their ﬁlial
mice.
Several studies have shown that the glutamatergic system plays
an important role in the neurobiology and treatment of depression,
probably through the N-methyl-D-aspartate (NMDA) receptor.
Indeed, NMDA receptor antagonists possess antidepressant activities
and conventional antidepressants are reported to decrease the
binding, expression and function of NMDA receptors (Sanacora
et al., 2008).
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neural cell death and the direct relationship between hippoccampal
and cortical damage and depressive disorders (Sapolsky, 2000), in
this study we have hypothesized that ferulic acid could display an an-
tidepressant property in the widely-accepted predictive models of
depression in mice, which are used to screen new antidepressant
drugs. For that we performed an investigation to verify the
antidepressant-like effect of ferulic acid by using the forced swim-
ming test (FST) and the tail suspension test (TST).
This study also aimed to investigate the participation of the sero-
tonergic system in the antidepressant-like effect of an acute adminis-
tration of ferulic acid in the TST and a possible interaction of ferulic
acid with conventional antidepressants.2. Material and methods
2.1. Animals
Male Swiss mice (30–40 g) were maintained at 21–23 °C with free
access to water and food, under a 12:12 h light/dark cycle (lights on
at 07:00 h). All manipulations were carried out between, 9:00 and
16:00 h, with each animal used only once. All procedures in this
study were performed in accordance with the National Institute of
Health Guide for the Care and Use of Laboratory Animals. The expe-
riments were performed after approval of the protocol by the Institu-
tional Ethics Committee (CEUA/UFSC) and all efforts were made to
minimize animals suffering and to reduce the number of animals
used in the experiments.2.2. Drugs and administration
Ferulic acid, N-{2-[4-(2-methoxy-phenyl)-1-piperazinyl]ethyl}-
N-(2-pyridynyl)cyclohexanecarboxamide (WAY100635), ketanserin
tartarate, ﬂuoxetine, paroxetine, and sertraline (all from Sigma
Chemical Company, St. Louis, MO, U.S.A.) were used. The drugs were
dissolved in saline and ferulic acid was diluted in saline containing
1% (v/v) Tween 80. The control animals received appropriate vehicle.
In order to investigate the antidepressant-like effect of ferulic acid,
it was administered at a dose range of 0.001–10 mg/kg, by oral route
(p.o.) 60 min before the FST, TST or open-ﬁeld test. To address some
of the mechanisms by which ferulic acid exerts antidepressant-like
action in the TST, animals were pre-treated with different pharmaco-
logical agents.
To investigate a possible contribution of the serotonergic system
(5-HT receptor subtypes) in the antidepressant-like effect of ferulic
acid, animals were pretreated with WAY100635 (0.1 mg/kg, a selec-
tive 5-HT1A receptor antagonist) by subcutaneous route (s.c.), ketan-
serin (5 mg/kg, a preferential 5-HT2A receptor antagonist) by
intraperitoneal route (i.p.), or vehicle and after 30 min, received feru-
lic acid (0.01 mg/kg, p.o.) or vehicle before being tested in the TST
60 min later. The drugs were administered in a volume of 10 mL/kg
body weight.
We also assessed the ability of ferulic acid to potentiate the
antidepressant-like effect of selective serotonin reuptake inhibitors
(SSRIs). To this end, mice received by p.o. route sub-effective dose
of ﬂuoxetine (5 mg/kg), paroxetine (0.1 mg/kg) or sertraline (1 mg/
kg) and immediately after a sub-effective dose of ferulic acid
(0.001 mg/kg, p.o.) or vehicle. Sixty minutes later, the TST or the
open-ﬁeld test was carried out.
The doses of the drugs used were selected on the basis of literature
data and of previous results from our laboratory which reported that
those drugs do not increase locomotor activity (Capra et al., 2010;
Cunha et al., 2008; Doyle and Shaw, 1998; Genedani et al., 1984;
Kaster et al., 2005; Mikolajczak et al., 2002).2.3. Forced swimming test (FST)
The FST was carried out in mice individually which were forced to
swim in an open cylindrical container (diameter 10 cm, height
25 cm), containing 19 cm of water at 25±1 °C; the total duration of
immobility during the 6-min test was scored as described previously
(Kaster et al., 2005; Zomkowski et al., 2010). Each mouse was judged
to be immobile when it ceased struggling and remained ﬂoating mo-
tionless in the water, making only those movements necessary to
keep its head above water.
2.4. Tail suspension test (TST)
The total duration of immobility induced by tail suspension was
measured according to the method of Steru et al. (1985). Mice both
acoustically and visually isolated were suspended 50 cm above the
ﬂoor by adhesive tape placed approximately 1 cm from the tip of
the tail. Immobility time was recorded during a 6-min test (Cunha
et al., 2008; Machado et al., 2007; Rodrigues et al., 2002). Mice were
considered immobile only when they hung passively and completely
motionless. The immobility time was recorded by an observer blind
to the drug treatment.
2.5. Open-ﬁeld behaviour
The ambulatory behaviour was assessed in an open-ﬁeld test as
described previously (Zomkowski et al., 2010). The open ﬁeld arena
used was a wooden box measuring 40×60 cm and 50 cm height
with the ﬂoor divided into 12 equal squares. At the start of each
trial a mouse was placed in the left corner of the ﬁeld and was
allowed to freely explore the arena. The number of squares crossed
with all paws (crossing) was counted in a 6 min session. The arena
ﬂoor was cleaned between the trials with a 10% ethanol solution
and the test was carried out in a temperature, noise, and light con-
trolled room.
2.6. Data analysis
Comparisons between treatment groups and control were per-
formed by one-way or two-way analyses of variance (ANOVA) fol-
lowed by Tukey's HSD test, when appropriate. A value of Pb0.05
was considered to be signiﬁcant.
3. Results
3.1. Effect of ferulic acid on the immobility time in the FST and TST and
locomotor activity in the open-ﬁeld test
The results illustrated in Fig. 1A and B show that ferulic acid (0.01,
0.1, 1 or 10 mg/kg) given by oral route decreased signiﬁcantly the im-
mobility time in the FST and in the TST. Fig. 1C shows that the admin-
istration of ferulic acid (dose range of 0.001–10 mg/kg, p.o.) produced
no effect in the open-ﬁeld test, indicating that a confounding locomo-
tor impairment can be discarded in the antidepressant-like effect ob-
served, in both FST and TST.
3.2. Investigation of the mechanisms underlying the antidepressant-like
effect of ferulic acid in the TST
3.2.1. Involvement of the serotonergic system
Fig. 2A shows the effect of the pretreatment of mice with
WAY100635 (0.1 mg/kg, s.c., a 5-HT1A receptor antagonist) and feru-
lic acid (0.01 mg/kg, p.o.) in the TST. The pretreatment with
WAY100635 was able to prevent the anti-immobility effect of ferulic
acid. The administration of WAY100635 alone or in combination with
ferulic acid did not affect the ambulation in the open-ﬁeld (Fig. 2B).
Fig. 1. Effect of the administration of ferulic acid (dose range 0.001–10 mg/kg, p.o.)
in the FST (panel A), in the TST (panel B), and in the open-ﬁeld test (panel C). Values
are expressed as mean±S.E.M. (n=6–9). *Pb0.05 and **Pb0.01 as compared with
the vehicle-treated group. A) F(5,31)=15.05, Pb0.01. B) F(5,38)=15.40, Pb0.01.
C) F(5,31)=1.01, P=0.43.
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(5 mg/kg, i.p., a 5-HT2A/2C receptor antagonist) on the anti-immobility
effect of ferulic acid (0.01 mg/kg, p.o.). The pretreatment with ketan-
serin blocked the decrease in immobility time produced by ferulic
acid in the TST. The administration of ketanserin alone or in combina-
tion with ferulic acid did not affect the ambulation in the open-ﬁeld
(Fig. 2D).
3.2.2. Interaction of ferulic acid with conventional antidepressants in the
TST
In this study the potential synergistic effect of the administration
of sub-effective doses of antidepressants and ferulic acid was also in-
vestigated. Fig. 3A shows that the administration of ferulic acid
(0.001 mg/kg, p.o.) boosted the antidepressant-like effect of ﬂuoxe-
tine (5 mg/kg, p.o.) in the TST. Previous studies from our group
(Cunha et al., 2008; Freitas et al., 2010; Machado et al., 2009)
reported that ﬂuoxetine (10 mg/kg, p.o.), paroxetine (1 mg/kg, p.o.)
or sertraline (10 mg/kg, p.o., unpublished result), caused a reduction
in the immobility time in the TST. The results depicted in Fig. 3Cshows that the combined administration of ferulic acid (0.001 mg/kg,
p.o.) and paroxetine (0.1 mg/kg, p.o.) reduced the immobility time of
mice submitted to the TST. Fig. 3E shows that the administration of ser-
traline (1 mg/kg, p.o.) exhibited a potent antidepressant-like effect
when combined with ferulic acid (0.001 mg/kg, p.o.). The results
obtained here revealed a synergistic antidepressant-like effect induced
by ﬂuoxetine, paroxetine or sertraline when co-administered with
ferulic acid in the TST.
Moreover, the effect of the treatment with antidepressants ﬂuox-
etine (5 mg/kg), paroxetine (0.1 mg/kg) or sertraline (1 mg/kg) and
ferulic acid alone or in combination was veriﬁed in the open-ﬁeld
test. The results depicted in Fig. 3B, D and F show that the administra-
tion of the antidepressants in combination with ferulic acid did not
alter the locomotor activity of mice in the open-ﬁeld test.
4. Discussion
There is a large number of current pharmacological treatments for
depression, but the success rate of medication is not more than
50–60% (Kiss, 2008) and most of them are poorly tolerated because
of adverse side effects (Guadarrama-Cruz et al., 2008). Therefore,
there is a need for research and development of more effective anti-
depressant therapies without any or with less adverse effects. In
this study, we have shown that the ferulic acid administered by oral
route produced a signiﬁcant antidepressant-like response in the FST
and TST. Noteworthy, ferulic acid was able to produce a synergistic
action with the conventional antidepressants, ﬂuoxetine, paroxetine
or sertraline, in the TST.
The FST and TST are widely used as behavioural tools for screening
antidepressant activity of several classes of drugs (Cryan et al., 2005).
In this study, the antidepressant-like effect of the ferulic acid was ob-
served at the same doses in both TST and FST (0.01–10 mg/kg, p.o.). A
previous study developed by Yabe et al. (2010) has reported that
ferulic acid (250 mg/kg) ameliorated the chronic mild stress-
induced depressive-like behaviour observed in the FST in mice. How-
ever, it should be considered that the above mentioned study has a
protocol of stress-induced depressive-like behaviour, different from
our experimental approach. In the present study, ferulic acid
(0.01–10 mg/kg) was effective in both FST and TST predictive tests
of antidepressant agents. Additionally, ferulic acid induces no dose–
response-related effect, as both low and high doses of that compound
decreased the immobility period. Therefore, it is possible that such
ﬁndings result from a saturation of ferulic acid sites of interaction,
since maximum effect was achieved at lower doses. Similar results
were found in a previous study performed with Aloysia gratissima
aqueous extract (10 mg/kg, p.o.) species having ferulic acid as the
major polyphenolic compound (Zeni et al., 2011), and with curcumin
(2.5–10 mg/kg, p.o.), a polyphenol isolated from Curcuma longa with
chemical similarity to ferulic acid (Xu et al., 2005).
The major neurochemical process known in depression is the im-
pairment of monoaminergic neurotransmission and the concomitant
decrease of extracellular concentration of noradrenaline and/or sero-
tonin (Schildkraut, 1965). Moreover, the serotonergic system in the
pathogenesis of depression is an important target for the conventional
pharmacotherapy (Duman et al., 1997; Wong and Licinio, 2001). The
antidepressants commonly affect serotonin balance, inhibiting seroto-
nin reuptake and also exertingmodulation of 5-HT1A and 5-HT2 recep-
tors (Cryan et al., 2005). In the present study, the administration of
WAY100635 (a competitive antagonist at the 5-HT1A receptors)
prevented the anti-immobility effect of ferulic acid in the TST, an
indicative that this 5-HT1A receptor subtype is involved in the
antidepressant-like effect of ferulic acid. According to results of our re-
search group (Machado et al., 2009) and Wang et al. (2008), it has
been demonstrated that the antidepressant-like effect of Rosmarinus
ofﬁcinalis and C. longa, which contain ferulic acid, was prevented by
5-HT1A antagonists in the TST and FST, respectively. Studies have
Fig. 2. Effect of the pretreatment of mice withWAY100635 (0.1 mg/kg, s.c., panel A) or ketanserin (5 mg/kg, i.p., panel C) on the anti-immobility effect of ferulic acid (0.01 mg/kg, p.o.) in
the TST and on the number of crossings in the open-ﬁeld tests (panels B and D, respectively). Values are expressed asmean±S.E.M. (n=6). **Pb0.01 compared with the vehicle-treated
control. #Pb0.01 as comparedwith the ferulic acid alone. A) Ferulic acid treatment [F(1,20)=96.01, Pb0.01]; WAY100635 pretreatment [F(1,20)=29.41, Pb0.01];WAY100635×ferulic
acid interaction [F(1,20)=53.84, Pb0.01]. B)WAY100635 pretreatment [F(1,20)=0.02, P=0.88]; ferulic acid treatment [F(1,20)=0.02, P=0.88]; WAY100635×ferulic acid interaction
[F(1,20)=0.81, P=0.38]. C) Ketanserin pretreatment [F(1,20)=45.74, Pb0.01]; ferulic acid treatment [F(1,20)=20.37, Pb0.01]; ketanserin×ferulic acid interaction [F(1,20)=21.02,
Pb0.01]. D) Ketanserin pretreatment [F(1,20)=1.26, P=0.27]; ferulic acid treatment [F(1,20)=1.26, P=0.27]; ketanserin×ferulic acid interaction [F(1,20)=0.12, P=0.73].
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of action of antidepressant drugs and compounds that could block
these receptors might be effective in producing antidepressant re-
sponses (Blier and Ward, 2003).
It was previously suggested that also an activation of the 5-HT2 re-
ceptors is implicated in the modulation of mood (Hoyer et al., 1986)
and these receptors have also been related to the aetiology of depres-
sion (Nestler et al., 2002). In addition, preclinical reports showed that
the preferential 5-HT2A receptor agonist R(−)-1-(2,5-dimethoxy-4-
iodophenyl)-2-aminopropane HCl (DOI) enhances the antidepressant-
like effect of some compounds in the FST (Khisti and Chopde, 2000;
Zomkowski et al., 2004). Since the antidepressant-like effect elicited
by ferulic acid in the TST was prevented by the pretreatment of mice
with ketanserin (a preferential 5-HT2A serotonin receptor antagonist),
it is also feasible to suggest the possible involvement of the 5-HT2A in
the antidepressant-like effect of ferulic acid. Our results are in accor-
dance with data from the literature showing that the reduction in the
immobility time elicited by scopoletin, a coumarin isolated from Polygala
sabulosa (Capra et al., 2010), and R. ofﬁcinalis (Machado et al., 2009) was
also prevented by the pretreatment with ketanserin, in the TST.
This study showed that the ferulic acid was able to produce a syner-
gistic antidepressant-like effect with some conventional antidepres-
sants, all SSRIs, ﬂuoxetine, paroxetine, and sertraline in the TST. This
effect was not accompanied by hyperlocomotion that could produce a
false positive antidepressant-like effect. Therefore, the present study
suggests that the combination of the ferulic acid with conventional an-
tidepressants might be an alternative approach to treat depression. In-
terestingly, Warner-Schmidt et al. (2011) suggested that anti-
inﬂammatory drugs decrease the antidepressant effects of SSRIs inmice and humans. Although ferulic acid was reported to have anti-
inﬂammatory properties (Jin et al., 2005; Kim et al., 2004; Perluigi et
al., 2006), it remains to be established if this effect would be produced
by very low doses of ferulic acid, such as the sub-effective dose
employed in the present study. However, given the potential role of in-
ﬂammatory factors in depression, it might be expected that antagonists
of this system would have beneﬁcial effects with respect to mood, or
could serve as an adjunct to more typical antidepressant medications.
Indeed, it was reported that cyclooxygenase-2 inhibitors may have pos-
itive effects in reducing depression in preclinical trials, and when
coupled to ﬂuoxetine the production of proinﬂammatory cytokines
was reduced and the antidepressant effects observed were more pro-
nounced comparatively to the elicitation with ﬂuoxetine alone
(Anisman, 2011). Besides, SSRIs such as ﬂuoxetine and paroxetine
also have anti-inﬂammatory effects (Maes et al., 2011).
The exact mechanism by which ferulic acid modulates 5-HT recep-
tors activity in order to produce an antidepressant-like effect is not
clear. It should be taken into account that ferulic acid has been
reported to act as a putative competitive antagonist of NMDA recep-
tors (Yu et al., 2006). The involvement of glutamate in the pathophys-
iology of depression has been suggested in several studies (for
review, see Sanacora et al., 2008). Increased levels of glutamate in
the frontal cortex in postmortem samples (Hashimoto et al., 2007)
and in the plasma of patients with depression (Mauri et al., 1998)
have been reported. Additionally, NMDA receptor antagonists possess
antidepressant properties and antidepressants have been reported to
reduce the binding, expression, and function of NMDA receptors
(Sanacora et al., 2008; Skolnick, 1999). Noteworthy, NMDA receptor
antagonists have been reported to increase serotonin release in the
Fig. 3. Effect of the administration of a sub-effective dose of ferulic acid (0.001 mg/kg, p.o.) in association with sub-effective doses of ﬂuoxetine (5 mg/kg, p.o.), paroxetine (0.1 mg/
kg, p.o) or sertraline (1 mg/kg, p.o.) in the TST (panels A, C and E, respectively) and in the open-ﬁeld test (panels B, D and F, respectively). Values are expressed as mean±S.E.M.
(n=6–8). *Pb0.05 and **Pb0.01 as compared with the vehicle-treated group. A) Fluoxetine pretreatment [F(1,24)=18.05, Pb0.01]; ferulic acid treatment [F(1,24)=26.29,
Pb0.01]; ﬂuoxetine×ferulic acid interaction [F(1,24)=13.65, Pb0.01]. B) Fluoxetine pretreatment [F(1,20)=0.02, P=0.89]; ferulic acid treatment [F(1,20)=0.69, P=0.41]; ﬂuox-
etine×ferulic acid interaction [F(1,20)=0.03, P=0.86]. C) Paroxetine pretreatment [F(1,28)=15.10, Pb0.01]; ferulic acid treatment [F(1,28)=8.91, Pb0.01]; paroxetine×ferulic
acid interaction [F(1,28)=5.70, Pb0.05]. D) Paroxetine pretreatment [F(1,20)=0.01, P=0.93]; ferulic acid treatment [F(1,20)=0.01, P=0.93]; paroxetine×ferulic acid interaction
[F(1,20)=0.28, P=0.60]. E) Sertraline pretreatment [F(1,28)=5.08, Pb0.05]; ferulic acid treatment [F(1,28)=29.36, Pb0.01]; sertraline×ferulic acid interaction [F(1,28)=6.53,
Pb0.05]. F) Sertraline pretreatment [F(1,20)=2.97, P=1.00]; ferulic acid treatment [F(1,20)=3.56, P=0.07]; sertraline×ferulic acid interaction [F(1,20)=0.54, P=0.47].
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Therefore, one possibility to account for this antidepressant-like ef-
fect of ferulic acid might be its action as a NMDA receptor antagonist,
thus affecting serotonin neurotransmission. In line with this, the ad-
ministration of antidepressants that increases the levels of serotonin
at the synapse modulates mood via different signalling transduction
pathways (D'Sa and Duman, 2002; Hashimoto, 2010). Therefore, the
possibility that ferulic acid exerts its action in the TST through an in-
teraction with NMDA receptors, thus, affecting serotonergic neuro-
transmission is feasible and deserves further studies.
In conclusion, in relation to the mechanism, our study provides
evidence for the involvement of serotonergic system in the
antidepressant-like effect of ferulic acid in the TST. The effect offerulic acid is prevented by 5-HT1A and 5-HT2 receptor, which are
both serotonergic antagonists, and is enhanced by antidepressants
that act as SSRIs. Further research will be necessary to clarify in
more details the exact mechanism by which ferulic acid induces
antidepressant-like effect.Acknowledgements
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